Biomarker Profiles Associated with COVID-19 Severity and Mortality
暂无分享,去创建一个
X. Muñoz | O. Roca | J. Ferrer | A. Pacheco | M. Cruz | S. Sánchez-Díez | M. de Homdedeu | Carlos Gómez-Ollés | D. Espejo
[1] A. Sette,et al. Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination , 2022, medRxiv.
[2] V. Poletti,et al. European Respiratory Society statement on long COVID follow-up , 2022, European Respiratory Journal.
[3] C. De Molo,et al. Spontaneous Evolution of COVID-19 Lung Sequelae: Results from a Double-Step Follow-Up , 2022, Respiration.
[4] X. Chen,et al. The Investigation of Pulmonary Function Changes of COVID-19 Patients in Three Months , 2022, Journal of healthcare engineering.
[5] S. Luzzi,et al. Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis , 2021, Cytokine.
[6] Ramezan Jafari,et al. Interleukin-1 in COVID-19 Infection: Immunopathogenesis and Possible Therapeutic Perspective. , 2021, Viral immunology.
[7] H. Rui,et al. Cytotoxic CD8-positive T-lymphocyte infiltration in the lungs as a histological pattern of SARS-CoV-2 pneumonitis , 2021, Pathology.
[8] T. Yin,et al. ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review , 2021, International journal of molecular sciences.
[9] R. Singh,et al. Role of toll‐like receptors in modulation of cytokine storm signaling in SARS‐CoV‐2‐induced COVID‐19 , 2021, Journal of medical virology.
[10] D. Eksombatchai,et al. Pulmonary function and six-minute-walk test in patients after recovery from COVID-19: A prospective cohort study , 2021, PloS one.
[11] S. Avdeev,et al. Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study , 2021, Cytokine.
[12] G. Jenkins,et al. COVID‐19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts , 2021, Immunological reviews.
[13] R. Okuda,et al. Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019 , 2021, Respiratory Investigation.
[14] I. Efremova,et al. Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19) , 2021, European Cytokine Network.
[15] O. Malaise,et al. YKL-40 as a new promising prognostic marker of severity in COVID infection , 2021, Critical Care.
[16] M. Bocchino,et al. Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia , 2021, International journal of environmental research and public health.
[17] C. Ranasinghe,et al. Interleukin-13 as a target to alleviate severe coronavirus disease 2019 and restore lung homeostasis , 2021, Journal of clinical and translational research.
[18] R. Heads,et al. COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation , 2021, Mediators of inflammation.
[19] R. Preissner,et al. IL-13 is a driver of COVID-19 severity , 2020, medRxiv : the preprint server for health sciences.
[20] L. Notarangelo,et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients , 2020, JCI insight.
[21] R. Kream,et al. Long-Term Respiratory and Neurological Sequelae of COVID-19 , 2020, Medical science monitor : international medical journal of experimental and clinical research.
[22] Keith Sigel,et al. An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.
[23] N. Laura,et al. Interleukin-6-based mortality risk model for hospitalised COVID-19 patients , 2020, Journal of Allergy and Clinical Immunology.
[24] Hedayat Sahraei,et al. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging” , 2020, Inflammation Research.
[25] J. Knight,et al. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease. , 2020, JCI insight.
[26] D. Bennett,et al. Serum KL‐6 concentrations as a novel biomarker of severe COVID‐19 , 2020, Journal of medical virology.
[27] K. Subbarao,et al. Respiratory Virus Infections: Understanding COVID-19 , 2020, Immunity.
[28] M. Rotondi,et al. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system , 2020, Cytokine & Growth Factor Reviews.
[29] L. Roncati,et al. Signals of Th2 immune response from COVID-19 patients requiring intensive care , 2020, Annals of Hematology.
[30] Georg Schett,et al. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? , 2020, Nature Reviews Immunology.
[31] Robert J. Mason,et al. Pathogenesis of COVID-19 from a cell biologic perspective , 2020, European Respiratory Journal.
[32] Quanyi Wang,et al. Viral load of SARS-CoV-2 in clinical samples , 2020, The Lancet Infectious Diseases.
[33] Chuan Qin,et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[35] R. Liu,et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors , 2020, Emerging microbes & infections.
[36] Kevin McCarthy,et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement , 2019, American journal of respiratory and critical care medicine.
[37] J. Barata,et al. Flip the coin: IL-7 and IL-7R in health and disease , 2019, Nature Immunology.
[38] K. Zorena,et al. Chitinases and immunity: Ancestral molecules with new functions. , 2016, Immunobiology.
[39] S. Stanojevic,et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.
[40] T. Fry,et al. Harnessing the biology of IL-7 for therapeutic application , 2011, Nature Reviews Immunology.
[41] B. Ma,et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. , 2011, Annual review of physiology.
[42] R. Flavell,et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13–induced tissue responses and apoptosis , 2009, The Journal of experimental medicine.
[43] L. Ware. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. , 2006, Seminars in respiratory and critical care medicine.
[44] N. Kohno,et al. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. , 2005, Biochemical and biophysical research communications.
[45] N. Kohno,et al. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. , 1997, American journal of respiratory cell and molecular biology.